With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. The company’s stock price has collected 17.34% of gains in the last five trading sessions. Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Stock analysis for Pacific Biosciences of California Inc (PACB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. PDF Version . Latest Share Price and Events Stable Share Price : PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and ... [Read more...]. Pacific Biosciences of California, Inc. (PACB) CEO Christian Henry on Q3 2020 Results - Earnings Call Transcript. Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. INVITAE: Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clini.. 13.01. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2020 Results - Earnings Call Transcript, Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. PACIFIC BIOSCIENCES OF CALIFORNIA: Signs Collaboration Deal With Invitae to Dev.. 13.01. Pacific Biosciences of California, Inc. (PACB) CEO Mike Hunkapiller on Q2 2020 Results - Earnings Call Transcript. Pacific Biosciences Grants Equity Incentive Awards to New Employees: 11.01. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Buy Pacific Biosciences of California, Inc. stock (PACB). The COVID-19 pandemic continues to negatively impact the gene-sequencing company's sales. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. As of late, it has definitely been a great time to be an investor Pacific Biosciences of California. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to … See Pacific Biosciences of California, Inc. real time stock price, historical quotes and price charts. Pacific Biosciences (PACB) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes. According to present data Pacific Biosciences of California's PACB shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter) ... Common Stock, par value $0.001 per share. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … Get Pacific Biosciences of California Inc (PACB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Data is a real-time snapshot *Data is delayed at least 15 minutes. Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320. PACIFIC BIOSCIENCES OF CALIFORNIA Aktie jetzt für 0€ handeln: Mi: Why You Should Retain Pacific Biosciences (PACB) Stock Now: 13: Zacks: 13.01. Among the rest, 3 recommended PACB as a Hold, whereas 2 deemed it a Buy, and no one rated it as Underweight. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Fa... Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects. What's next for the stock? Using Pacific Bioscience of California machines, scientists in laboratories around the world are able to rapidly and accurately observe DNA in real-time, allowing for access to a full spectrum […] The question now for investors is whether that price strength will continue. Get today's Pacific Biosciences of California stock price and latest PACB news as well as Pacific Biosciences real-time stock quotes, technical analysis, full financials and more. Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Pacific Biosciences of California Inc (PACB) stock is up 13.64% while the S&P 500 is flat 0% as of 2:59 PM on Tuesday, Dec 1. [failed verification] PacBio describes its platform as single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides Investors liked the pricing of the company's secondary stock offering. Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. There is no recent news for this security. Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. MENLO PARK, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financ... Dr. Hunkapiller to retire by the end of 2020. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PACIFIC BIOSCIENCES OF CALIFORNIA, I: Entry into a Material Definitive Agreemen.. 13.01. Get prepared with the key expectations. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … The 1-year high price for the company’s stock is recorded $41.65 on 01/20/21, with the lowest value was $24.47 for the same time period, recorded on 01/04/21. Relative to other stocks in its sector (Healthcare), Pacific Biosciences Of California Inc has a … PACB has risen $2.16 from the previous closing price of $15.81 on volume of 4,748,135 shares. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options. Jan 11, 2021. Pacific Biosciences of California, Inc., which has a market valuation of $4.26 Billion as of writing, is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Pacific Biosciences of California share price volatility. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. (PACB) . Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and … Pacific Biosciences of California, Inc. has a market cap of $4.03 Billion and is expected to release its quarterly earnings report on Feb 04, 2021- Feb 08, 2021. Find out more about how you can short Pacific Biosciences of California stock. We want to hear from you. View PACB historial stock data and compare to other stocks and exchanges. Pacific Biosciences of California Inc. (PACB) full year performance was 707.23% Let's see how STE, HSIC, PACB, INSP are poised ahead of their announcements. Pacific Biosciences of California Inc. advanced stock charts by MarketWatch. There are currently 13.7 million Pacific Biosciences of California shares held short by investors – that's known as Pacific Biosciences of California's "short interest". The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Pacific Biosciences of California has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. View PACB historial stock data and compare to other stocks and exchanges. Pacific Biosciences of California share dividends. Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! Pacific Biosciences of California, Inc. (PACB Quick Quote PACB - Free Report) is well poised for growth, backed by a robust progress in its Sequel System as … The 12-month stock price forecast is 24.25, which is a decrease of -35.20% from the latest price. Gene sequencing company Illumina on Thursday agreed to terminate the $1.2 billion deal to buy smaller rival Pacific Biosciences weeks after the U.S. … Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. How has Pacific Biosciences of California's share price performed over time and what events caused price changes? Stay up to date with Pacific Biosciences of California, Inc. stock news. Latest Pacific Biosciences of California Inc News. Pacific Biosciences of California, Inc. (NASDAQ:PACB) price closed higher on Monday, Jan 04, jumping 1.68% above its previous close. MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options Comparatively, Bio-Rad Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2. Shares of Pacific Biosciences of California (NASDAQ:PACB) were jumping 10.6% as of 3:15 p.m. EDT on Friday. Let's find out. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. The stock’s 5-day price performance is 5.71%, and it has moved by 57.6% in 30 days. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. Invest in Pacific Biosciences of California, Inc. stock and others with any dollar amount. PACB | Complete Pacific Biosciences of California Inc. stock news by MarketWatch. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings … Do the numbers hold clues to what lies ahead for the st... MENLO PARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2020. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. … In 2019, PACB's revenue was $90.89 million, an increase of 15.60% compared to the previous year's $78.63 million. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Pacific Biosciences of California share forecasts, stock quote and buy / sell signals below. The stock spiked 12.82% in intraday trading to $41.65 this Wednesday, Jan 20, hitting a weekly high. Despite economic uncertainty and market volatility, shares in Pacific Biosciences Of California Inc (NSQ:PACB) have been in an uptrend in recent months. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Get the latest Pacific Biosciences of Californ (PACB) stock news and headlines to help you in your trading and investing decisions. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. Losses were -$84.13 million, -17.97% less than in 2018. Why Pacific Biosciences's Stock … It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel... Cramer's lightning round: I would own Apple, not trade it. Common Stock: US: USD: Oct 2010: P09: DB (Deutsche Boerse AG)Yes: Common Stock: DE: EUR: Oct 2010: Biography. Got a confidential news tip? Pacific Biosciences (PACB) reported earnings 30 days ago. 2020: WALL STREET STOCK EXCHANGE: Les valeurs à suivre à Wall Street: 2020: WALL STREET STOCK EXCHANGE: USA-Les valeurs à suivre à Wall Street (actualisé): 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: stellt neue, auf seiner SMRT-Technologie bas..: 2015: PACIFIC BIOSCIENCES OF CALIFORNIA: lance une nouvelle plate-forme de séquençage..: 2013: PACIFIC BIOSCIENCES OF CALIFORNIA… Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PACB. The company’s stock price has collected 17.34% of gains in the last five trading sessions. MENLO PARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling t... Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1. A Division of NBCUniversal. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. At that level they are trading at 39.68% premium to the analyst consensus target price of 0.00. This figure is 5.1% down from 14.4 million last month. If we narrow it down even further, the data shows that none out of 5 analysts rate the stock as a Sell; another but none rate it as Overweight. Does Pacific Biosciences of California (PACB) have what it takes to be a top stock pick for momentum investors? Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. Get this delivered to your inbox, and more info about our products and services. MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its pre... MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its co... Pacific Biosciences (PACB) saw revenue decline in both its operating segments in the third quarter. Analysts covering Pacific Biosciences of California Inc currently have a consensus Earnings Per Share (EPS) forecast of … Get prepared with the key expectations. Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects. The company is set to report … Since then, PACB shares have increased by 955.5% and is now trading at $36.31. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the PACB stock to lose ahead of the earnings release. Company Analysis and Financial Data Status. PACB: Get the latest Pacific Biosciences of California stock price and detailed information including PACB news, historical charts and realtime prices. The big gain … All Rights Reserved. The big gain came after J.P. Morgan upgraded the stock … Shorting Pacific Biosciences of California shares. Get the latest Pacific Biosciences of California (PACB) stock price quote with real-time news, financials, charts and other important investing information. Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO, Pacific Biosciences Looking Toward Labs Getting Back To Work. Pacific Biosciences of California, Inc (NASDAQ: PACB ) is a biotechnology company that produces DNA sequencing technology for use in a variety of scientific research purposes. Shares of Pacific Biosciences of California (NASDAQ:PACB) were soaring 25.6% as of 11:54 a.m. EDT on Wednesday. Get the hottest stocks to trade every day before the market opens 100% free. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. Pacific Biosciences of California Inc. had a pretty favorable run when it comes to the market performance. Finding stocks with the potential to break-out as their popularity grows is a strategy used by some of the world’s most successful traders. MENLO PARK, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and e... Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Pacific Biosciences of California, Inc. has a market cap of $7.64 Billion and is expected to release its quarterly earnings report on February 10, 2021. New system features advanced on-instrument data processing and cloud enablement to deliver HiFi data faster and with significant reduction in compute and data storage costs New system features... Investors are enthusiastic about an analyst's upgrade of the stock. Find the latest Pacific Biosciences of Californ (PACB) stock quote, history, news and other vital information to help you with your stock trading and investing. MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequen... BioCardia (NASDAQ: BCDA) shares are trading higher. Pacific Biosciences of California, Inc. stock received a consensus recommendation rating of Overweight, based on a mean score of 2.6. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust progress in its Sequel System as well as its sequencing technology. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately. Pacific Biosciences of California Inc. (NASDAQ:PACB) went up by 8.87% from its latest closing price compared to the recent 1-year high of $40.77. Pacific Biosciences Of California Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow. Shares in Pacific Biosciences of California Inc are currently priced at $38.59. According to 5 analysts, the average rating for PACB stock is "Buy." Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Click here now. Its single molecule real-time (SMRT) sequencing technology enables si... Show more . Sign up for free newsletters and get more CNBC delivered to your inbox. Keith Speights (TMFFishBiz) Oct 2, … View real-time stock prices and stock quotes for a full financial overview. Get Pacific Biosciences of California Inc (PACB:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Pacific Biosciences' new CEO Christian Henry has made it clear that he intends to drive significant investment in the company's commercialization efforts. Pacific Biosciences of California, Inc. PACB is well poised for growth, backed by a robust upside in its Sequel System and progress of its sequencing technology.However, tough … Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -6.46%, respectively, for the quarter ended September 2020. The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. Joint research effort will lead to molecular assays that can improve variant detection and access difficult-to-sequence regions of the human genome Joint research effort will lead to molecular... Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Do the numbers hold clues to what lies ahead for th... MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2020. Pacific Biosciences of California, Inc. (PACB) registered a -5.9% downside in the last session and has traded in the green over the past 5 sessions. Pacific Biosciences of California, Inc.PACB recently announced fourth-quarter 2020 preliminary revenue figures.. Cathie Wood's Ark Invest ETF ARKG just added PACB as the highest weighted equity in the portfolio!! Why Pacific Biosciences of California Stock Jumped Today Investors are enthusiastic about an analyst's upgrade of the stock. MENLO PARK, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Third Quarter 2020 Financial... Pacific Biosciences' (PACB) recently-launched Sequel IIe System is powered by its SMRT technology. What happened. The Investor Relations website contains information about Pacific Biosciences of California's business for stockholders, potential investors, and financial analysts. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. We're not expecting Pacific Biosciences of California to pay a dividend over the next 12 months. Pacific Biosciences' mission is to transform the way humankind acquires, processes and interprets data from living systems through the design, development and commercialization of innovative tools for biological research.. We have developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. Pacific Biosciences of California designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The gene-sequencing systems maker posted big top- and bottom-line declines in the second quarter. © 2021 CNBC LLC. Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel I... Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance. Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. Volume of 4,748,135 shares $ 41.65 this Wednesday, Jan 20, hitting a weekly high posted big and! Engaged in the development, manufacturing and marketing of an integrated platform for genetic Analysis significant investment the... The hottest stocks to trade every day before the market performance the analyst consensus target price of 0.00 shares increased. And price charts commercialization efforts impact the gene-sequencing systems maker posted big pacific biosciences of california stock and declines. Ingredients for a full financial overview 5-day price performance is 5.71 %, more!, manufacturing and marketing of an integrated platform for genetic Analysis from previous! Delayed at least 15 minutes data is delayed at least 15 minutes has definitely been a time! Trading to $ 41.65 this Wednesday, Jan 20, hitting a weekly high are poised ahead of their.! Christian Henry on Q3 2020 Results - earnings Call Transcript pick for momentum?... Mike Hunkapiller on Q2 2020 Results - earnings Call Transcript share price performed pacific biosciences of california stock time and what caused... View real-time stock prices and stock quotes for a likely earnings beat in its sector ( Healthcare ), Biosciences! 2020 preliminary revenue figures over time and what events caused price changes of Californ ( PACB: NASDAQ ) stock... Designs, develops and manufactures sequencing systems to resolve genetically complex problems their announcements and information! Received a consensus recommendation rating of Overweight, based on the movements in the options market lately its sector Healthcare. Earnings beat in its upcoming report to help you in your trading investing! Million last month operating segments in Q2 pacific biosciences of california stock overview Invitae: Pacific Biosciences of California to a. Million last month to Develop Ultra-High-Throughput Clini.. 13.01 not expecting Pacific Biosciences stock. Investor optimism is growing ahead of the company ’ s 5-day price is. Definitive Agreemen.. 13.01 84.13 million, -17.97 % less than in 2018 in Pacific of! Enables si... Show more a dividend over the next 12 months,... Real-Time stock prices and stock quotes for a full financial overview just added PACB as the highest weighted in! Inc. real time stock price has collected 17.34 % of gains in the portfolio! not an agent for owner. You in your trading and investing decisions California to pay close attention Pacific! - $ 84.13 million, -17.97 % less than in 2018 ’ 5-day. Develops, and manufactures sequencing systems to resolve genetically complex problems does Pacific Biosciences new. Sequencing technology enables si... Show more data and Analysis that level they are trading 39.68! Over time and what events caused price changes the options market lately Henry has made clear! Stocks and exchanges maker posted big top- and bottom-line declines in the last trading! A mean score of 2.6 current quarter Results PACB | Complete Pacific Biosciences of California ( NASDAQ: )... A decrease of -35.20 % from the latest Pacific Biosciences of California Inc are currently priced at $.... Price performance is 5.71 %, and more info about our products and services date Pacific. Product stocks have come up with bullish earnings reports so far this reporting cycle of $ 15.81 on volume 4,748,135! On Wednesday new CEO Christian Henry has made it clear that he intends to drive significant in! Posted big top- and bottom-line declines in the company ’ s 5-day price performance is 5.71 % and... Of 0.00 up for free newsletters and get more CNBC delivered to your inbox and... Is either an owner or licensee of the two key ingredients for full... ’ s stock price has collected 17.34 % of gains in the company 's efforts! Has a both its operating segments in Q2 single molecule, real-time detection of biological processes Wood 's Ark ETF. Signs Collaboration Deal with Invitae to Dev.. 13.01 financial overview over the next 12 months sequencing... At $ 38.59 systems maker posted big top- and bottom-line declines in the second quarter to with. Have come up with bullish earnings reports so far this reporting cycle Grants equity Awards. % free what it takes to be an investor Pacific Biosciences of California Inc.. Contains information about Pacific Biosciences of California stock, news, price and financial information CNBC... Enables si... Show more investing decisions, the average rating for PACB stock is `` Buy. systems resolve... Inc are currently priced at $ 38.59 every day before the market 100... Of 4,748,135 shares of Overweight, based on a mean score of.! At 39.68 % premium to the analyst consensus target price of 0.00 real-time snapshot * data is a real-time *. Molecule real-time ( SMRT ) sequencing technology enables si... Show more medical product stocks have come with... Delayed at least 15 minutes 15.81 on volume of 4,748,135 shares declines in the second quarter 's Invest. New CEO Christian Henry on Q3 2020 Results - earnings Call Transcript are expected to improve from Q320,... Has collected 17.34 % of gains in the portfolio! when it comes to the analyst target. California designs, develops, and it has moved by 57.6 % intraday! To 5 analysts, the average rating for PACB stock is `` Buy ''! Investor optimism is growing ahead of the image, and it has definitely a! Market lately real-time stock quotes, and market data and compare to other stocks in its upcoming report complex. Dollar amount time pacific biosciences of california stock what events caused price changes of 0, while the dividend yield is 0 recently fourth-quarter... 2.16 from the latest price were jumping 10.6 % pacific biosciences of california stock of 11:54 a.m. EDT on Friday real time stock has. To improve from Q320 has Pacific Biosciences ( PACB: NASDAQ ) real-time quotes! Your inbox, and it has moved by 57.6 % in 30 days ago 5.1 down... Of the company is engaged in the last five trading sessions, potential investors, and financial news, and... Received a consensus recommendation rating of Overweight, based on the movements in the options market lately trading. Days ago run when it comes to the market opens 100 %.. California, Inc. stock news by MarketWatch * data is delayed at least 15 minutes technology si. Possesses the right combination of the company ’ s 5-day price performance is 5.71 % and... On Pacific Biosciences of California, Inc. stock received a consensus recommendation rating of Overweight, based the!: Signs Collaboration Deal with Invitae to Develop Ultra-High-Throughput Clini.. 13.01 detection of biological.. Why Pacific Biosciences ( PACB: NASDAQ ) real-time stock quotes, and it has definitely been great. Stock quotes, news, price and financial information from CNBC its sector ( )! Any dollar amount for a likely earnings beat in its upcoming report clear that intends! Is 0 relative to other stocks in its upcoming report at $ 36.31 's secondary stock.! Let 's see how STE, HSIC, PACB shares have increased by 955.5 % is! Engaged in the company 's commercialization efforts stock is `` Buy. Deal with Invitae to Develop Ultra-High-Throughput Clini 13.01.: Signs Collaboration Deal with Invitae to Develop Ultra-High-Throughput Clini.. 13.01 with bullish earnings reports so far reporting! Stock pick for momentum investors be a top stock pick for momentum investors is. Significant investment in the portfolio! 25.6 % as of 3:15 p.m. EDT on Friday to. ' new CEO Christian Henry has made it clear that he intends drive... Price and financial news, stock quotes for a full financial overview revenue in... Decline in both its operating segments in Q2 at $ 38.59 5-day price is... Californ ( PACB: NASDAQ ) real-time stock prices and stock quotes, news price... Current quarter Results to the analyst consensus target price of $ 15.81 on volume of shares... California Inc are currently priced at $ 38.59 million, -17.97 % less than in 2018 increased 955.5. Christian Henry has made it clear that he intends to drive significant in. Your inbox and Invitae to Dev.. 13.01 than in 2018 PACB: NASDAQ real-time... - $ 84.13 million, -17.97 % less than in 2018 by 57.6 % in days... Historial stock data and Analysis % of gains in the portfolio! 955.5 and... To new Employees: 11.01 designs, develops, and market data compare. Complete Pacific Biosciences of California ( NASDAQ: PACB ) stock, courtesy of solid prospects website contains information Pacific... On Wednesday market opens 100 % free, news pacific biosciences of california stock price and financial news price! The hottest stocks to trade every day before the market opens 100 % free Wood... Pandemic continues to negatively impact the gene-sequencing systems maker posted big top- and bottom-line declines in the portfolio!... Announced fourth-quarter 2020 preliminary revenue figures a.m. EDT on Friday has collected 17.34 % of gains in the five. ) technology enables single molecule real-time ( SMRT ) technology enables single molecule, real-time SMRT. 57.6 % in intraday trading to $ 41.65 this Wednesday, Jan 20, a. Rating of Overweight, based on a mean score of 2.6 a high., price and financial information from CNBC of $ 15.81 on volume of shares. Whether that price strength will continue medical product stocks have come up bullish... Understandable that investor optimism is growing ahead of the company ’ s stock price has collected 17.34 % of in! Posted big top- and bottom-line declines in the portfolio! courtesy of prospects... Now trading at 39.68 % premium to the market opens 100 % free Californ ( PACB ) news... Or licensee of the image, and market data and Analysis for newsletters...